Bicara Therapeutics Inc.
bicara.comBicara Therapeutics Inc (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company that develops drug candidates for oncology indications. The company generates no product revenue, funding its operations through capital raises rather than commercial sales. As of the 10-K filed March 30, 2026, Bicara carries operating lease commitments of $1,794 thousand (less than $604 thousand due beyond three years), is audited by KPMG LLP in Boston, and operates under CEO Claire Mazumdar, Ph.D. The company is subject to healthcare pricing regulations including the ACA and Inflation Reduction Act Manufacturer Discount Program, and faces data privacy obligations under HIPAA and GDPR. Bicara's financial statements cover fiscal years ended December 31, 2025 and December 31, 2024, reflecting accumulated comprehensive losses consistent with a pre-commercial development stage. The company filed its S-1 registration statement on August 22, 2024.
Products & Services
Drug candidates in oncology, described as being in clinical development. No specific approved products or named drug candidates are identified in the provided filing excerpts.
Revenue Model
Pre-revenue clinical-stage company. No product sales disclosed in the filing excerpts. Operations are funded through equity capital raises, including proceeds from the IPO registration process initiated in August 2024.
Customers & Markets
No commercial customers disclosed. End market is oncology patients and, upon any future approval, healthcare facilities, physicians, and other healthcare providers. Subject to Medicare Part D and Medicaid reimbursement frameworks.
Geographic Exposure
U.S.-headquartered. Subject to U.S. federal and state healthcare and tax law. Also subject to GDPR obligations covering the EEA and U.K., indicating some operations or data collection outside the U.S.
Source: SEC 10-K, filed 2026-03-30
Financial Snapshot
Loading...
